This is a pilot study; patients will receive 131-I apamistamab prior to CAR T-cell infusion in order to determine the maximum tolerated dose of 131-I apamistam…

B-ALLDLBCLB ALL+8 more

~Estimated

~$10 – $6,250

Memorial Sloan Kettering Cancer CenterNCT04512716

Phase 1

A Phase 1 Study of SynKIR-310, Autologous T Cells Transduced With CD19 KIR-CAR, in Participants With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

This first-in-human (FIH) trial is designed to assess the safety, feasibility and preliminary efficacy of a single intravenous (IV) dose of SynKIR-310 administ…

B Cell LymphomaNHL, AdultMantle Cell Lymphoma+23 more

~Estimated

~$10 – $8,750

Verismo TherapeuticsNCT06544265